Form 4: Emergent BioSolutions Executive Receives RSU Grant

Simon C. Lowry, SVP of R&D and CMO at Emergent BioSolutions, acquired 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• Simon C. Lowry, SVP of R&D and CMO, was granted 100,111 restricted stock units (RSUs).
• The grant was contingent upon shareholder approval of the Amended 2006 Stock Incentive Plan, which occurred on April 29, 2026.
• Following this transaction, the reporting person beneficially owns 177,914 shares of common stock.
• The RSUs vest in three equal annual installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Successful shareholder approval of the Amended Stock Incentive Plan provides the company with necessary tools for talent retention.

Negatives

• The issuance of 100,111 RSUs results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon continued service, creating potential retention risk if the executive departs.
• The value of the equity grant is subject to market volatility of the underlying common stock.

Future Outlook

The RSUs are scheduled to vest in three annual installments, incentivizing the executive's continued tenure and performance over the coming years.

Management Comments

• The grant was approved by the Compensation Committee subject to stockholder approval of the Amended Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive incentives with long-term R&D milestones and corporate growth.

Comparison to Industry Standards

• The use of multi-year vesting schedules for executive equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• The reliance on shareholder-approved incentive plans is a standard regulatory requirement for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and conversion of these RSUs into common stock.

Next Steps

• Vesting of the first installment of RSUs on the anniversary of the approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation